ASA 404

Known as: ASA-404, ASA404 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
024620082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
5,6-Dimethylxanthenone 4-acetic acid (DMXAA), also known as ASA404 and vadimezan, is a potent tumor blood vessel-disrupting agent… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2012
2012
The flavone acetic acid derivative DMXAA [5,6-dimethylXAA (xanthenone-4-acetic acid), Vadimezan, ASA404] is a drug that displayed… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined… (More)
Is this relevant?
2010
2010
BACKGROUND ASA404 (5,6-dimethylxanthenone-4-acetic acid) is a small-molecule, flavonoid tumor-vascular disrupting agent. Pooled… (More)
Is this relevant?
2010
2010
PURPOSE This randomized phase II study evaluated ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) in combination with… (More)
Is this relevant?
2009
2009
This single-arm phase II study evaluated the tumor-vascular disrupting agent ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic… (More)
Is this relevant?
2009
2009
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of… (More)
Is this relevant?
2009
2009
The sustenance of most solid tumors including head and neck cancers (HNCs) is strongly dependent on the presence of a functioning… (More)
Is this relevant?
2008
2008
ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA). This… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?